We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 581% below its sector, cheaper than its peers on earnings.
Beijing Leadman Biochemistry Co.,Ltd. is a prominent entity within the People's Republic of China, specializing in the entire lifecycle – from research and development to manufacturing and distribution – of advanced in vitro diagnostic (IVD) solutions. Its product portfolio encompasses a comprehensive range of biochemical raw materials. This includes critical components like enzymes, coenzymes, antibodies, various buffers, enzyme substrates, culture media, staining reagents, and amino acids. These essential ingredients serve a diverse array of sectors, notably biotechnology, clinical diagnostics, pharmaceutical development, and chemical manufacturing. Beyond raw materials, Leadman also provides specialized biochemistry diagnostic and complementary reagents. Furthermore, the company supplies a sophisticated selection of medical instrumentation. This lineup features the EnigmaML, an automated molecular testing platform designed for both clinical laboratories and various point-of-care settings like clinics and pharmacies. Another key offering is the DiaSys InnovaStar, a compact automated POCT analyzer that delivers laboratory-grade diagnostic accuracy. Customers also benefit from the DiaSys Respons, a versatile random access benchtop analyzer; the CI1000 automatic chemiluminescence immunoassay analyzers; and the IDS-isys, an instrument engineered to boost operational performance and efficiency. Established in 1997, Beijing Leadman Biochemistry maintains its corporate headquarters in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300289.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
